Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Berruti, A.
Right arrow Articles by Angeli, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Berruti, A.
Right arrow Articles by Angeli, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 12:S153-S157, 2001
© 2001 European Society for Medical Oncology

Reviews

Potential clinical value of circulating chromogranin A in patients with prostate carcinoma

A. Berruti1, L. Dogliotti1, A. Mosca1, G. Gorzegno1, E. Bollito4, M. Mari3, R. Tarabuzzi3, M. Poggio3, M. Torta1,2, D. Fontana3 and A. Angeli2

1 Dipartimento di Scienze Cliniche e Biologiche, Università di Thrino, Oncologia Medica Azienda Ospedaliera San Luigi, Orbassano (TO), Italy
2 Dipartimento di Scienze Cliniche e Biologiche, Università di Thrino, Medicina Inerna Azienda Ospedaliera San Luigi, Orbassano (TO), Italy
3 Dipartimento di Scienze Cliniche e Biologiche, Università di Thrino, Urologia Azienda Ospedaliera San Luigi, Orbassano (TO), Italy
4 Dipartimento di Scienze Cliniche e Biologiche, Università di Thrino, Dipartimento di Anatomia Patologica Azienda Ospedaliera San Luigi, Orbassano (TO), Italy

Correspondence to: Prof. L. Dogliotti Oncologia Medica Azienda Ospedaliera San Luigi Regione Gonzole 10 10043 Orbassano (TO) Italy E-mail: luigi.dogliotti{at}unito.it

Background: Neuroendocrine (NE) differentiation of prostate adenocarcinoma has received increasing attention in recent years as a result of possible implications for prognosis and therapy. The presence of NE tumor subpopulation can be gauged non invasively by measuring circulating levels of secretory products, primarily chromogranin A (CgA).

Methods: This article provides a review on published papers evaluating circulating CgA in prostate cancer patients.

Results: Circulatmg CgA levels were found to be higher in prostate cancer patients than in patients with benign or premalignant prostatic diseases. In patients with malignancy, they correlated either to the stage of disease or to the condition of hormone refractoriness. CgA levels did not correlate with serum prostate specific antigen (PSA) and were supranormal in the majority of advanced patients with PSA within normality. In hormone refractory cases, elevated CgA was a significant predictor of poor prognosis, independently from serum PSA. CgA values were not substantially affected by either endocrine therapy or chemotherapy. They were found to increase during androgen deprivation in some cases and this trend preceded that of PSA. The administration of a somatostatin analog in hormone refractory cases was able to reduce plasma CgA values consistently.

Conclusions: Present data suggest a potential role of circulating CgA in the management of prostate cancer patients. CgA determination may be useful diagnostically and prognostically and could offer complementary information with respect to PSA. Serial evaluation of circulating CgA could provide information on changes in the NE phenotype expression as a consequence of tumor progression and/or treatment administration.

chromogranin A, neuroendocrine differentiation, prostate cancer, prostate specific antigen


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Endocr Relat CancerHome page
A Berruti, A Mosca, M Tucci, C Terrone, M Torta, R Tarabuzzi, L Russo, C Cracco, E Bollito, R M Scarpa, et al.
Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease
Endocr. Relat. Cancer, March 1, 2005; 12(1): 109 - 117.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.